Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A controlled-release tablets for mild to moderate Alzheimer's disease dementia
CTR20252594Phase 3Active
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Aug 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Huperzine A in Alzheimer's disease (AD), sponsored by Wanbangde Pharmaceutical Holding Group. Started Aug 2025; status: active.
02
Drugs
Huperzine A
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20252594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252594.